Researchers have found that the FOLFOX chemotherapy regimen in a colorectal cancer model activated NF-κB, subsequently increasing the production of TNF and IL-6 and consequently leading to local inflammation and mucosal damage [50]. Here, TNF is linked to colorectal cancer.